Leveraging Diagnostics to Realize the Full Potential of Precision Oncology
07th July 2017
As we approach the twentieth anniversary of the approval of Herceptin, the field of precision oncology has never been more exciting or dynamic, and utility seems to be broadly recognized. Precision...
It is critical for US biotech companies to understand the needs of European payers
17th October 2013
There is increasing divergence between the evidence regulators need for approval, and that needed by payers for reimbursement. Whilst ignoring the needs of European payers before entering Phase 3...
Content not found